Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Priority claimed from PCT/EP2008/004563external-prioritypatent/WO2008155033A1/en
Publication of BRPI0813099A2publicationCriticalpatent/BRPI0813099A2/en
BRPI0813099-0A2A2007-06-202008-06-07
(OXAZOLIDINON-5-IL-METIL) -2-THIOPHEN-CARBOXAMIDES REPLACED AND THEIR USE IN THE BLOOD COAGULATION FIELD
BRPI0813099A2
(en)
Balanced physiological monitoring and treatment system
Legal Events
Date
Code
Title
Description
B08F
Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
Free format text:
REFERENTE A 7A ANUIDADE.
B25D
Requested change of name of applicant approved
Owner name:
BAYER PHARMA AKTIENGESELLSCHAFT (DE)
B25A
Requested transfer of rights approved
Owner name:
BAYER INTELLECTUAL PROPERTY GMBH (DE)
B08K
Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
Free format text:
EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.